نتایج جستجو برای: fms like tyrosine kinase 3

تعداد نتایج: 2525800  

Journal: :Hypertension 2012
Robert W Powers James M Roberts Daniel A Plymire Dominick Pucci Saul A Datwyler Don M Laird David C Sogin Arun Jeyabalan Carl A Hubel Robin E Gandley

Preeclampsia is a heterogeneous syndrome affecting 3% to 5% of all pregnancies. An imbalance of the antiangiogenic and proangiogenic factors, soluble receptor fms-like tyrosine kinase 1 and placental growth factor (PGF), is thought to contribute to the pathophysiology of preeclampsia. Maternal plasma PGF and soluble receptor fms-like tyrosine kinase 1 were quantified by specific immunoassays in...

Journal: :Journal of cell science 2013
Susanne Köthe Jörg P Müller Sylvia-Annette Böhmer Todor Tschongov Melanie Fricke Sina Koch Christian Thiede Robert P Requardt Ignacio Rubio Frank D Böhmer

FMS-like tyrosine kinase 3 with internal tandem duplication (FLT3 ITD) is an important oncoprotein in acute myeloid leukemia (AML). Owing to its constitutive kinase activity FLT3 ITD partially accumulates at endomembranes, a feature shared with other disease-associated, mutated receptor tyrosine kinases. Because Ras proteins also transit through endomembranes we have investigated the possible e...

Journal: :Molecular cancer therapeutics 2013
Ruwanthi N Gunawardane Ronald R Nepomuceno Allison M Rooks Jeremy P Hunt Jill M Ricono Barbara Belli Robert C Armstrong

Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML). FLT3-activating internal tandem duplication (ITD) mutations are found in approximately 30% of patients with AML and are associated with poor outcome in this patient population. Quizartinib (AC220) has previously been shown to be a potent and selective FLT3 inhibitor. In the current study, we exp...

2015
Silvia Sironi Michaela Wagner Alexander Kuett Heidrun Drolle Harald Polzer Karsten Spiekermann Christina Rieger Michael Fiegl

Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase constitutively expressed by acute myeloid leukaemia (AML) blasts. In addition, 25% of AML patients harbour a FLT3-ITD mutation, associated with inferior outcome due to increased relapse rate. Relapse might be propagated by interactions between AML blasts and the bone marrow microenvironment. Besides cellular elements of the microen...

Journal: :iranian journal of pharmaceutical research 0
ramin shekarriz md, board certified hematologist-oncologist, assistant professor, department of hematology-oncology, cancer research center, imam khomeini hospital, mazandaran university of medical sciences, sari, iran neda koulaeinejad pharmd, resident of clinical pharmacy, faculty of pharmacy, mazandaran university of medical sciences, sari, iran anahita nosrati md, board certified pathologist, assistant professor, department of pathology, imam khomeini hospital, mazandaran university of medical sciences, sari, iran ebrahim salehifar pharmd, board certified clinical pharmacist, associated professor, department of clinical pharmacy, pharmaceutical research center, mazandaran university of medical sciences, sari, iran

sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. it was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. it has several adverse reactions on multi organ systems including hematologic system. although the neutropenia and thrombocytopenia commonly happens as gra...

Journal: :international journal of hematology-oncology and stem cell research 0
gholamreza bahoush pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran mardavizh albouyeh pediatric hematology-oncology department, shohada general hospital, shahid-beheshti university of medical sciences, tehran, iran parvaneh vossough 1pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran

introduction: imatinib mesylate is a selective inhibitor of tk and is considered now to be the frontline therapeutic agent during the chronic phase of cml. we have evaluated the efficacy of it on children with chronic-phase of cml. patients and methods: in a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of cml. s...

Journal: :Blood 2016
Shaoguang Li

In this issue of Blood, Dany et al demonstrate a critical role of the ceramideregulated signaling pathway in inducing mitophagy to cause cell death and overcome drug resistance of acute myeloid leukemia (AML) cells carrying internal tandem duplication (ITD) of the Fms-like tyrosine kinase 3 (FLT3) gene. Inhibition of FLT3-ITD signaling through altering ceramide-involved lipid metabolism provide...

2013
Marianna Greco Giovanni Caocci Antonio Ledda Adriana Vacca Marcella Arras Ivana Celeghini Giorgio La Nasa

Despite major advances in the treatment of acute promyelocytic leukemia (APL), the problem of early death (ED) remains unsolved. Alongside the currently known clinical and hematological risk factors, prognostic significance has been attributed to internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD), hypogranular variant morphology, and the bcr-3 isoform of PML-RAR ...

Mandana Beigi Boroujeni Mohammadreza Gholami, Nasim Beigi Boroujeni,

Objective(s): Progestrone is a prequisite for pre-implantation angiogenesis and induce decidual angiogenesis. It is unknown the effect of progestrone administration on the endometrium of hyperstimulated mice at pre-implantation time. Material and Methods: Adult female NMRI mice were divided in three groups [control group, ovarian stimulated group and progestrone treated mice after ovarian stimu...

2018
Riad El Fakih Walid Rasheed Yousef Hawsawi Maamoun Alsermani Mona Hassanein

The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generati...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید